Medivir AB (MVIRb.F) Release: Primary Efficacy and Safety Data From Four Phase III Japanese Studies of Simeprevir Presented at The Japan Society of Hepatology
6/6/2013 9:20:46 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Stockholm, Sweden — Medivir AB (OMX: MVIR) reports that its partner Janssen
Pharmaceutical R&D Ireland (Janssen) today announced primary efficacy and safety
results from four Japanese phase III clinical studies demonstrating that the use
of the investigational NS3/4A protease inhibitor simeprevir (TMC435) led to
sustained virologic response 12 weeks after the end of treatment (SVR12) in
patients with genotype 1 hepatitis C, when administered once daily with
pegylated interferon and ribavirin. The four studies examined the use of
simeprevir in genotype 1 chronic hepatitis C patients who were treatment naïve,
as well as patients who were non-responders to prior therapy or relapsed
following treatment with pegylated interferon with or without ribavirin.
Help employers find you! Check out all the jobs and post your resume.
comments powered by